Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Neuronascent.

    Client Virtual Booth

    NEURONASCENT

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Neuronascent
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    6030 Day Break Circle A150 – PMB244 Clarksville, MD 21029
    Telephone
    Telephone
    +1 240-876-7496
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://neuronascent.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/neuronascent-inc/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease

    Details:

    NNI-362, Neuronascent’s lead, patented, new chemical entity, was developed to reverse age-related disorders by producing new neurons to replace those lost due to chronic neurodegeneration.


    Lead Product(s): NNI-362

    Therapeutic Area: Neurology Product Name: NNI-362

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 08, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome

    Details:

    NNI-351 is Neuronascent’s lead, patented, new chemical entity aimed at reversing developmental disorders by producing new neurons postnatally to enhance neurogenesis that is slowed during early development in diseases such as FXS.


    Lead Product(s): NNI-351

    Therapeutic Area: Genetic Disease Product Name: NNI-351

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 24, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimers Disease

    Details:

    NNI-362, at the two multi-doses, 120 mg and 240 mg, was shown to significantly reduce p-tau181 levels versus pre-treatment levels in study participants, also showed a significant reduction of an Alzheimer’s disease pathological biomarker.


    Lead Product(s): NNI-362

    Therapeutic Area: Neurology Product Name: NNI-362

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: National Institute on Aging

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 30, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer’s Disease

    Details:

    NNI-362 is Neuronascent's lead, patented, new chemical entity developed to reverse age-related disorders by producing new neurons to replace those lost due to chronic neurodegenerative disorders.


    Lead Product(s): NNI-362

    Therapeutic Area: Neurology Product Name: NNI-362

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: National Institute on Aging

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 29, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search